Evidence map›Paper›PMID 41025645›Full record

Trial reportAntimicrobial agents and chemotherapy2025

A first-in-human phase I study to evaluate the safety, tolerability, and pharmacokinetics of a novel anti-influenza agent suraxavir marboxil in healthy Chinese subjects.

Qingqing Wu, Lang Lv, Shousheng Yan, Yijun Wang, Qian Chen, Wenjing Xu, Yun Liu, Wei Wang, Jingying Jia, Chen Yu and 2 more

Abstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qingqing Wu *Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, Shanghai, China.ORCID 0000-0003-4105-290X
Lang Lv *Jiangxi Qingfeng Pharmaceutical Co., Ltd., Jiangxi, China.
Shousheng YanJiangxi Qingfeng Pharmaceutical Co., Ltd., Jiangxi, China.
Yijun WangDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, Shanghai, China.
Qian ChenDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, Shanghai, China.
Wenjing XuDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, Shanghai, China.
Yun LiuDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, Shanghai, China.
Wei WangDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, Shanghai, China.
Jingying JiaDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, Shanghai, China.
Chen YuDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, Shanghai, China.
Jingjing ChenJiangxi Qingfeng Pharmaceutical Co., Ltd., Jiangxi, China.
Yanmei LiuDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, Shanghai, China.ORCID 0000-0003-1174-8447

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Suraxavir marboxil (GP681) is a prodrug of a novel polymerase acidic protein inhibitor, and its metabolite GP1707D07 prevents the replication of influenza virus by selectively inhibiting the cap-dependent nucleic acid endonuclease of influenza virus. This study evaluates the safety, tolerability, and pharmacokinetics of suraxavir marboxil after a single dose and assesses the effect of a high-fat, high-calorie meal on the pharmacokinetics of suraxavir marboxil in healthy Chinese subjects. The study included two parts: single ascending-dose study (SAD) and food effect study (FE). In SAD, subjects were randomized to single-dose suraxavir marboxil (20, 40, 60, or 80 mg) or placebo. In FE, subjects (

Indexed as

Antiviral AgentsAdolescentAdultEast Asian PeopleFemaleFood-Drug InteractionsHealthy VolunteersHumansInfluenza, HumanMaleMiddle AgedYoung AdultAntiviral Agentshealthy subjectsinfluenzapharmacokineticspolymerase acidic protein inhibitorsafetysuraxavir marboxil

Identifiers

PMID41025645
PMCPMC12587533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.